USD10
MIRM Shares
About Mirum PharmaceuticalsMirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.
USD10
MIRM Shares
About Mirum PharmaceuticalsMirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.
Stats
TRADING WINDOW
Closed
OPENS AT
Jul 13 at 1:30 PM GMT+0
MARKET CAP
$7.26B
OPEN PRICE
$120.18
LOW (1Y)
$50.25
HIGH (1Y)
$130.00
LOW (24H)
$117.18
HIGH (24H)
$120.89
VOLUME (24H)
$601.14K
11.5%
Price history
Time | Price | Change |
|---|---|---|
Today | $120.18 | |
1 Day | $122.50 | |
1 Week | $121.96 | |
1 Month | $99.35 | |
1 Year | $53.28 |
Past performance is not a reliable indicator of future results.
Discover more
Popular prediction markets
Popular price predictions
Legal
Information is provided for informational purposes only, and is not investment advice. This is not an invitation, inducement or recommendation to buy any particular asset, or to employ any particular investment strategy. Coinbase makes no representation as to the accuracy, suitability or validity of any information provided.All ticker names are trademarks of their respective holders. Any ticker reference does not imply affiliate with or endorsement by a third-party. Real-time prices are sourced from third parties, but not from all markets. Source: Nasdaq Last Sale. Morningstar data ©2026.